About Blood Cancer Treatment (Leukaemia, Lymphoma & Myeloma)
Blood cancers are treated by haemato-oncologists rather than surgeons. The three broad groups, leukaemia, lymphoma and multiple myeloma, are distinct diseases with distinct treatment pathways, and each has subtypes that change the plan significantly.
This guide explains what the hospital assesses and what to ask. It is background reading, not medical advice.
Diagnosis drives the plan
Precise subtyping matters more here than in most cancers. A bone marrow aspiration and biopsy, flow cytometry, cytogenetics and molecular studies are usually needed before a plan can be given. For lymphoma, a lymph node biopsy with immunohistochemistry and a PET-CT are typically required.
Partner hospitals will often repeat or extend testing done elsewhere. That is not duplication for its own sake: treatment intensity is decided on risk stratification, and that depends on laboratory detail.
Treatment approaches
Chemotherapy and targeted therapy
Most blood cancers are treated primarily with drugs, given in cycles over months. Some leukaemias are managed with oral targeted therapy taken long term. Some aggressive leukaemias require prolonged inpatient admission during induction.
Immunotherapy
Monoclonal antibodies are standard in several lymphomas and in myeloma. CAR T-cell therapy is available in India at a small number of centres for selected relapsed or refractory cases; ask specifically whether it applies to you and where it would be delivered.
Bone marrow transplant
Also called haematopoietic stem cell transplant. It may be autologous, using your own stem cells, or allogeneic, using a matched donor. Allogeneic transplant requires donor identification and HLA matching, which has to be resolved before travel can be planned.
Why stays are longer here
Induction chemotherapy and transplant both involve periods when the immune system is severely suppressed and infection risk is high. This requires isolation facilities, close monitoring and a stay measured in weeks. Travelling home between phases is often not possible.
Ask the hospital for a realistic total duration, including the post-transplant monitoring period, and plan accommodation for an accompanying attendant on that basis.
Questions worth asking the treating hospital
What exactly is the subtype and risk group? Is transplant part of the plan, and if so autologous or allogeneic? If allogeneic, how is the donor identified and what does that add to the timeline? How long must I remain in India after the last cycle? What infection precautions will I need, and for how long?
Ask the hospital for its own transplant volumes and outcomes. These vary between centres and only the hospital can give you its figures.
How Massvaa Care helps
We share your reports with the oncology teams at partner hospitals, return their written plan and itemised estimate on hospital letterhead, and coordinate the visa invitation, arrival and accommodation. We do not give medical opinions and we do not take a share of your treatment cost. You pay the hospital directly.
Any range quoted before the tumour board has reviewed your case is indicative only. Cancer costs vary widely with stage, subtype and the number of cycles, so the hospital's written estimate is the figure to rely on.
